Govt Job: For Pharmacist in Department of Atomic Energy

The Indira Gandhi Centre for Atomic Research [IGCAR], the second largest establishment of the Department of Atomic Energy next to the Bhabha Atomic Research Centre, was set up at Kalpakkam, 80 KMs south of Chennai [MADRAS], in 1971 with the main objective of conducting a broad based multidisciplinary programme of scientific research and advanced engineering, directed towards the development of sodium cooled Fast Breeder Reactor [FBR] technology, in India.

This is part of the second stage of Indian Atomic Energy Programme, which is aimed at preparing the country for utilization of the extensive Thorium reserves and providing means to meet the large demands of electrical energy in 21st century.

Online Interview through Skype for filling up the following post on locum basis (purely temporary) in DAE Hospital, Kalpakkam/Anupuram will be held as detailed below:

Post : Pharmacist/B

No. of Post :01 (One)

Educational Qualification : HSC.(10+2)+ 2 years Diploma in Pharmacy + 6 months training in Pharmacy + Registration as a Pharmacist with Central and State Pharmacy council.

Consolidated Monthly Pay : Rs.40610/- (Plus 2628/- as House Rent Allowance if applicable)

Age limit : not to exceed 50 years as on the date of interview

General Conditions:
(a) Selection for the above post is purely on a temporary basis. The maximum period of appointment will be six months. However, such a locum appointment shall not exceed 89 days at a time.

(b) Selected candidates will be provided Hostel Accommodation on their taking up of the appointment, on payment basis if required. They will be entitled for House Rent Allowance (HRA) if own arrangement for accommodation is made.

(c) Interested candidates may forward enclosed Application in the prescribed form(word format) along with self attested Xerox copies of date of birth, educational qualification in a single PDF file through email: recruitgso@qmail.com latest by 27.11.2021 at 2400 hrs.

(d) Please enclose all the certificates and mark sheets ( year wise) of educational qualification in a single PDF file.

(e) In case a University gives grades/CGPA, CGPA equivalent percentage approved by the University may be provided.

(f) Details of screened-in candidates shall be displayed in GSO website igcar.qov.in/qso and shall be intimated via their respective email IDs

(g) Incomplete application and application without relevant proof of experience/qualification, year wise marks sheet etc. shall be summarily rejected.

(h) If the number of applications received are more, GSO reserves the right to restrict the number of candidates based on the percentage of marks obtained and their clinical experience

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre